<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFOTAXIME- cefotaxime sodiumÂ injectionÂ </strong><br>West-Ward Pharmaceutical Corp<br></p></div>
<h1>Cefotaxime for Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9d0a9fbd-841e-4723-ba51-65af60a6fbda"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx</span> ONLY</p>
<table>
<col>
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">
<span class="Bold">PHARMACY BULK PACKAGE â€“ NOT FOR DIRECT INFUSION</span>Â </td></tr></tbody>
</table>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefotaxime for Injection, USP (cefotaxime sodium) and other antibacterial drugs, Cefotaxime for Injection, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_e47021e3-7d05-4eaf-a9af-7bcab6d1e499"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Sterile cefotaxime sodium is a semisynthetic, broad spectrum cephalosporin antibiotic for parenteral administration. It is the sodium salt of 7-[2-(2-amino-4-thiazolyl) glyoxylamido]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicycloâ€‡[4.2.0]â€‡oct-2-ene-2-carboxylateâ€‡72â€‡(Z)-(o-methyloxime), acetate (ester). Cefotaxime for Injection, USP contains approximately 50.5 mg (2.2 mEq) of sodium per gram of cefotaxime activity. Solutions of Cefotaxime for Injection, USP range from very <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow to light amber depending on the concentration and the diluent used. The pH of the injectable solutions usually ranges from 5.0 to 7.5. The CAS Registry Number is 64485-93-4.</p>
<div class="Figure"><img alt="Chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561&amp;name=cefotaxime-for-injection-pbp-1.jpg"></div>
<p>C<span class="Sub">16</span>H<span class="Sub">16</span>N<span class="Sub">5</span>NaO<span class="Sub">7</span>S<span class="Sub">2</span>Â Â  MW 477.45</p>
<p>Cefotaxime for Injection, USP is supplied as a dry powder in Pharmacy Bulk Packages containing cefotaxime sodium equivalent to 10 g of cefotaxime. FURTHER DILUTION IS REQUIRED BEFORE USE. A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use, which contains many single doses. This Pharmacy Bulk Package is for use in a pharmacy admixture service; it provides many singles doses of cefotaxime for addition to suitable parenteral fluids in the preparation of admixtures for intravenous infusion. (SeeÂ <span class="Bold"><a href="#LINK_d73f4210-34b9-40b5-8670-470fd844c25a">DOSAGE AND ADMINISTRATION</a></span> and <span class="Italics"><a href="#LINK_508fd51b-2913-4bf4-9e39-b14c4c371098">DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_97f0dcd1-5ea9-4737-a206-89a161150dd3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Following IM administration of a single 500 mg or 1 g dose of cefotaxime to normal volunteers, mean peak serum concentrations of 11.7 and 20.5 mcg/mL respectively were attained within 30Â minutes and declined with an elimination half-life of approximately 1 hour. There was a doseâ€‘dependent increase in serum levels after the IV administration of 500 mg, 1 g, and 2 g of cefotaxime (38.9, 101.7, and 214.4 mcg/mL respectively) without alteration in the elimination half-life. There is no evidence of accumulation following repetitive IV infusion of 1 g doses every 6 hours for 14 days as there are no alterations of serum or renal clearance. About 60% of the administered dose was recovered from urine during the first 6 hours following the start of the infusion.</p>
<p>Approximately 20-36% of an intravenously administered dose of <span class="Sup">14</span>C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite. The desacetyl metabolite has been shown to contribute to the bactericidal activity. Two other urinary metabolites (M<span class="Sub">2</span> and M<span class="Sub">3</span>) account for about 20-25%. They lack bactericidal activity.</p>
<p>A single 50 mg/kg dose of cefotaxime was administered as an intravenous infusion over a 10- to 15-minute period to 29 newborn infants grouped according to birth weight and age. The mean half-life of cefotaxime in infants with lower birth weights (â‰¤1500 grams), regardless of age, was longer (4.6 hours) than the mean half-life (3.4 hours) in infants whose birth weight was greater than 1500 grams. Mean serum clearance was also smaller in the lower birth weight infants. Although the differences in mean half-life values are statistically significant for weight, they are not clinically important. Therefore, dosage should be based solely on age. (See <span class="Bold"><span class="Bold"><a href="#LINK_d73f4210-34b9-40b5-8670-470fd844c25a">DOSAGE AND ADMINISTRATION</a></span>Â </span>section.)</p>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_5383a41b-4191-4879-8ab4-6ba01f146d7a"></a><a name="section-3.1"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First">A single intravenous dose and oral dose of probenecid (500 mg each) followed by two oral doses of probenecid 500 mg at approximately hourly intervals administered to three healthy male subjects receiving a continuous infusion of cefotaxime increased the steady-state plasma concentration of cefotaxime by approximately 80%. In another study, administration of oral probenecid 500Â mg every 6 hours to six healthy male subjects with cefotaxime 1 gram infused over 5 minutes decreased the total clearance of cefotaxime by approximately 50%.</p>
<p>Additionally, no disulfiram-like reactions were reported in a study conducted in 22 healthy volunteers administered cefotaxime and ethanol.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="LINK_a5d578e7-3355-4b4c-83fb-517b4fdc41e5"></a><a name="section-3.2"></a><p></p>
<h2><span class="Bold">Microbiology</span></h2>
<p class="First"><span class="Italics">Mechanism of Action<br></span>Cefotaxime sodium is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefotaxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. </p>
<p><span class="Italics">Mechanism of Resistance<br></span>Resistance to cefotaxime is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability.</p>
<p>Susceptibility to cefotaxime will vary geographically and may change over time; local susceptibility data should be consulted, if available. Cefotaxime has been shown to be active against most isolates of the following bacteria both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in theÂ <span class="Bold"><span class="Bold"><a href="#LINK_cf9960b6-00dc-45c8-ae26-ee1388cdb1ee">INDICATIONS AND USAGE</a></span></span>Â section:</p>
<p><span class="Underline">Gram-positive bacteria</span><span class="Bold"><br></span><span class="Italics">Enterococcus </span>spp. <span class="Sup">a</span><span class="Italics"><br></span><span class="Italics">Staphylococcus aureus </span>(methicillin-susceptible isolates only)<br><span class="Italics">Staphylococcus epidermidis<br></span><span class="Italics">Streptococcus pneumoniae<br></span><span class="Italics">Streptococcus pyogenes </span>(Group A beta-hemolytic streptococci)<br><span class="Italics">Streptococcus </span>spp. (Viridans group streptococci)</p>
<p><span class="Underline">Gram-negative bacteria<br></span><span class="Italics">Acinetobacter </span>spp.<br><span class="Italics">Citrobacter </span>spp.<span class="Sup"> b</span><br><span class="Italics">Enterobacter </span>spp.<span class="Sup"> b</span><br><span class="Italics">Escherichia coli</span><span class="Sup"> b</span><br><span class="Italics">Haemophilus influenzae<br></span><span class="Italics">Haemophilus parainfluenzae<br></span><span class="Italics">Klebsiella </span>spp. (including <span class="Italics">Klebsiella pneumoniae</span>)<span class="Sup"> b</span><br><span class="Italics">Morganella morganii</span><span class="Sup"> b</span><br><span class="Italics">Neisseria gonorrhoeae </span>(including beta-lactamase-positive and negative <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)<br><span class="Italics">Neisseria meningitidis<br></span><span class="Italics">Proteus mirabilis</span><span class="Sup"> b</span><br><span class="Italics">Proteus vulgaris </span><span class="Sup">b</span><br><span class="Italics">Providencia rettgeri</span><span class="Sup"> b</span><br><span class="Italics">Providencia stuartii </span><span class="Sup">b</span><br><span class="Italics">Serratia marcescens</span><span class="Sup"> b</span></p>
<p><span class="Sup">a</span><span class="Italics">Enterococcus </span>species may be intrinsically resistant to cefotaxime.<br><span class="Sup">b </span>Most extended spectrum beta-lactamase (ESBL)-producing and carbapenemase-producing isolates are resistant to cefotaxime.</p>
<p><span class="Underline">Anaerobic bacteria<br></span><span class="Italics">Bacteroides </span>spp., including some isolates of <span class="Italics">Bacteroides fragilis<br></span><span class="Italics">Clostridium </span>spp. (most isolates of <span class="Italics">Clostridium difficile </span>are resistant)<br><span class="Italics">Fusobacterium </span>spp. (including <span class="Italics">Fusobacterium nucleatum</span>)<br><span class="Italics">Peptococcus </span>spp.<br><span class="Italics">Peptostreptococcus </span>spp.</p>
<p>The following <span class="Italics">in vitro </span>data are available, <span class="Bold">but their clinical significance is unknown</span>. At least 90 percent of the following microorganisms exhibit an <span class="Italics">in vitro </span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoint for cefotaxime. However, the efficacy of cefotaxime in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms has <span class="Bold">not been</span> established in adequate and well-controlled clinical trials.</p>
<p><span class="Underline">Gram-negative bacteria<br></span><span class="Italics">Providencia </span>spp.<br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>spp. (including <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhi</span>)<br><span class="Italics">Shigella </span>spp.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_de264aa0-2e54-46d6-9fb3-969b081358fc"></a><a name="section-3.3"></a><p></p>
<h2><span class="Underline"><span class="Italics">Susceptibility Test Methods</span></span></h2>
<p class="First">When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d5a856ce-79fb-4e1e-9d37-1f9930e63beb"></a><a name="section-3.3.1"></a><p></p>
<h3><span class="Underline"><span class="Italics">Dilution techniques:</span></span></h3>
<p class="First">Quantitative methodsÂ are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICsÂ  provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method (broth or agar) <span class="Sup">1,2</span>. The MIC values should be interpreted according to the criteria provided in Table 1.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f6bed523-3a76-4cb8-be12-650088579dfa"></a><a name="section-3.3.2"></a><p></p>
<h3><span class="Underline"><span class="Italics">Diffusion techniques:</span></span></h3>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method<span class="Sup">2,3</span>. This procedure uses paper disks impregnated with 30 mcg cefotaxime to test the susceptibility of microorganisms to cefotaxime. The disk diffusion interpretive criteria are provided in Table 1.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b4ebc352-7301-466b-a6de-960e253b4a16"></a><a name="section-3.3.3"></a><p></p>
<h3><span class="Italics"><span class="Underline">Anaerobic techniques:</span></span></h3>
<p class="First">For anaerobic bacteria, the susceptibility to cefotaxime as MICs can be determined by a standardized agar test method<span class="Sup">3,4</span>. The MIC values obtained should be interpreted according to the criteria provided in Table 1.</p>
<table>
<caption><span>Table 1: Susceptibility Test Interpretive Criteria for Cefotaxime</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><p class="First">The current absence of data on resistant isolates precludes defining any category other than â€œSusceptibleâ€?. If isolates yield MIC results other than susceptible, they should be submitted to a reference laboratory for additional testing.</p></dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd><p class="First"><span class="Italics">Haemophilus </span>spp includes only isolates of <span class="Italics">H. influenzae </span>and <span class="Italics">H. parainfluenzae</span>.</p></dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd><p class="First">Disc diffusion interpretive criteria for cefotaxime discs against Streptococcus pneumoniae are not available, however, isolates of pneumococci with oxacillin zone diameters of &gt;20 mm are susceptible (MIC â‰¤0.06 mcg/mL) to penicillin and can be considered susceptible to cefotaxime. <span class="Italics">S. pneumoniae </span>isolates should not be reported as penicillin (cefotaxime) resistant or intermediate based solely on an oxacillin zone diameter of â‰¤ 19 mm. The cefotaxime MIC should be determined for those isolates with oxacillin zone diameters â‰¤ 19 mm.</p></dd>
<dt><a name="footnote-4" href="#footnote-reference-4">Â§</a></dt>
<dd><p class="First">Other Non-Enterobacteriaceae include <span class="Italics">Pseudomonas </span>spp. and other nonfastidious, glucose-nonfermenting, gram-negative bacilli, but exclude <span class="Italics">Pseudomonas aeruginosa</span>, <span class="Italics">Acinetobacter </span>spp., <span class="Italics">Burkholderia cepacia</span>, <span class="Italics">Burkholderia mallei</span>, <span class="Italics">Burkholderia pseudomallei</span>, and <span class="Italics">Stenotrophomonas maltophilia</span>.</p></dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Pathogen</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span><br>(mcg/mL)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Disk Diffusion Zone Diameters (mm)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">(S)<br>Susceptible</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">(I)<br>Intermediate</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">(R)<br>Resistant</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">(S)<br>Susceptible</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">(I)<br>Intermediate</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">(R)<br>Resistant</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Acinetobacter spp.</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16-32</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥64</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥23</td>
<td class="Botrule Lrule Rrule Toprule" align="center">15-22</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤14</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Enterobacteriaceae</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥26</td>
<td class="Botrule Lrule Rrule Toprule" align="center">23-25</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤22</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Haemophilus </span>spp<span class="Italics">.<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a>Â </span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥26</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Neisseria gonorrhoeae<a href="#footnote-1" class="Sup">*</a>Â </span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤0.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥31</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Neisseria meningitidis<a href="#footnote-1" class="Sup">*</a>Â </span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤0.12</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥34</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Streptococcus pneumoniae<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a></span> <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> isolates</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤0.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Streptococcus pneumoniae<a href="#footnote-3" class="Sup">â€¡</a></span> non-<span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> isolates </td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Streptococcus </span>spp. beta-hemolytic group<a href="#footnote-1" class="Sup">*</a>Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤0.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥24</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Viridans group streptococci </td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥28</td>
<td class="Botrule Lrule Rrule Toprule" align="center">26-27</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤25</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Other <span class="Italics">Non-Enterobacteriaceae<a name="footnote-reference-4" href="#footnote-4" class="Sup">Â§</a>Â </span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16-32</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥64</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â -</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Anaerobic bacteria (agar method) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¤16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">32</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â‰¥64</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â -</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
<td class="Botrule Lrule Rrule Toprule" align="center">-</td>
</tr>
<tr class="Last"><td colspan="7">Â Susceptibility of staphylococci to cefotaxime may be deduced from testing only penicillin and either cefoxitin or oxacillin. </td></tr>
</tbody>
</table>
<br><p>A report of <span class="Italics">Susceptible</span> indicates that the antimicrobial is likely inhibit growth of the pathogen if the antimicrobial compound reaches the concentration at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site necessary to inhibit growth of the pathogen. A report of <span class="Italics">Intermediate</span> indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of <span class="Italics">Resistant</span> indicates that the antimicrobial is not likely inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be selected.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c98e199a-b9dd-4de6-a45f-31826556fe4c"></a><a name="section-3.3.4"></a><p></p>
<h3><span class="Italics"><span class="Underline">Quality Control: </span></span></h3>
<p class="First">Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test<span class="Sup">1,2,3,4,</span>. Standard cefotaxime sodium powder should provide the following range of MIC values noted in Table 2. For the diffusion technique using the 30 mcg disk, the criteria in Table 2 should be achieved.</p>
<table>
<caption><span>Table 2: Acceptable Quality Control Ranges for Cefotaxime </span></caption>
<col>
<col>
<col>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd><p class="First">Using the Reference Agar Dilution procedure.</p></dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></span>Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â <span class="Bold">Minimum Inhibitory<br>Concentrations (mcg/mL)</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">Disk Diffusion Zone<br>Diameters (mm)</span>Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Escherichia coli ATCC 25922</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0.03-0.12</td>
<td class="Botrule Lrule Rrule Toprule" align="center">29-35Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Staphylococcus aureus ATCC 29213</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1-4Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">-Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Staphylococcus aureus ATCC 25923</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â -</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 25-31</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Pseudomonas aeruginosa ATCC 27853</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 8-32</td>
<td class="Botrule Lrule Rrule Toprule" align="center">18-22Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Haemophilus influenzae ATCC 49247</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0.12-0.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 31-39</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Streptococcus pneumoniae ATCC 49619</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.03-0.12Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 31-39</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Neisseria gonorrhoeae ATCC 49226</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.015-0.06Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 38-48</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Bacteroides fragilis<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></span><span class="Italics">ATCC 25285</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 8-32</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â -</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Bacteroides thetaiotaomicron<a href="#footnote-5" class="Sup">*</a></span><span class="Italics">ATCC 29741</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16-64Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â -</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">Eubacterium lantem<a href="#footnote-5" class="Sup">*</a></span><span class="Italics">ATCC 43055Â </span>Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">64-256Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â -</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_cf9960b6-00dc-45c8-ae26-ee1388cdb1ee"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4c726c81-94a8-433c-a6dd-d00f90f3da3f"></a><a name="section-4.1"></a><p></p>
<h2><span class="Bold">Treatment</span></h2>
<p class="First">Cefotaxime for Injection, USP is indicated for the treatment of patients with serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the diseases listed below.</p>
<p><span class="Bold">(1) <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span>, </span>including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, caused by <span class="Italics">Streptococcus pneumoniae </span>(formerly <span class="Italics">Diplococcus pneumoniae</span>), <span class="Italics">Streptococcus pyogenes* </span>(Group A streptococci) and other streptococci (excluding enterococci, e.g., <span class="Italics">Enterococcus faecalis</span>), <span class="Italics">Staphylococcus aureus </span>(penicillinase and non-penicillinase producing), <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella </span>species, <span class="Italics">Haemophilus influenzae </span>(including ampicillin resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Haemophilus parainfluenzae</span>, <span class="Italics">Proteus mirabilis</span>, <span class="Italics">Serratia marcescens*</span>, <span class="Italics">Enterobacter </span>species, indole positive <span class="Italics">Proteus </span>and <span class="Italics">Pseudomonas </span>species (including <span class="Italics">P. aeruginosa</span>).</p>
<p><span class="Bold">(2) Genitourinary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span>. <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span> caused by <span class="Italics">Enterococcus </span>species, <span class="Italics">Staphylococcus epidermidis</span>, <span class="Italics">Staphylococcus aureus*</span>, (penicillinase and non-penicillinase producing), <span class="Italics">Citrobacter </span>species, <span class="Italics">Enterobacter </span>species, <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella </span>species, <span class="Italics">Proteus mirabilis</span>, <span class="Italics">Proteus vulgaris*</span>, <span class="Italics">Providencia stuartii</span>, <span class="Italics">Morganella morganii*</span>, <span class="Italics">Providencia rettgeri*</span>, <span class="Italics">Serratia marcescens </span>and <span class="Italics">Pseudomonas </span>species (including <span class="Italics">P. aeruginosa</span>). Also, uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> (cervical/urethral and rectal) caused by <span class="Italics">Neisseria gonorrhoeae</span>, including penicillinase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<p><span class="Bold">(3) Gynecologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, </span>including <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span>, <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span> and pelvic <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span> caused by <span class="Italics">Staphylococcus epidermidis</span>, <span class="Italics">Streptococcus </span>species, <span class="Italics">Enterococcus </span>species, <span class="Italics">Enterobacter </span>species*, <span class="Italics">Klebsiella </span>species*, <span class="Italics">Escherichia coli</span>, <span class="Italics">Proteus mirabilis</span>, <span class="Italics">Bacteroides </span>species (including <span class="Italics">Bacteroides fragilis*</span>), <span class="Italics">Clostridium </span>species, and anaerobic cocci (including <span class="Italics">Peptostreptococcus </span>species and <span class="Italics">Peptococcus </span>species) and <span class="Italics">Fusobacterium </span>species (including <span class="Italics">F. nucleatum*</span>).</p>
<p>Cefotaxime for Injection, USP, like other cephalosporins, has no activity against <span class="Italics">Chlamydia trachomatis</span>. Therefore, when cephalosporins are used in the treatment of patients with <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> and <span class="Italics">C. trachomatis </span>is one of the suspected pathogens, appropriate antiâ€‘chlamydial coverage should be added.</p>
<p><span class="Bold">(4) <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>/<span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span> </span>caused by <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella </span>species, and <span class="Italics">Serratia marcescens</span>, <span class="Italics">Staphylococcus aureus </span>and <span class="Italics">Streptococcus </span>species (including <span class="Italics">S. pneumoniae</span>).</p>
<p><span class="Bold">(5) Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </span>caused by <span class="Italics">Staphylococcus aureus </span>(penicillinase and non-penicillinase producing), <span class="Italics">Staphylococcus epidermidis</span>, <span class="Italics">Streptococcus pyogenes </span>(Group A streptococci) and other streptococci, <span class="Italics">Enterococcus </span>species, <span class="Italics">Acinetobacter </span>species*, <span class="Italics">Escherichia coli</span>, <span class="Italics">Citrobacter </span>species (including <span class="Italics">C. freundii*</span>), <span class="Italics">Enterobacter </span>species, <span class="Italics">Klebsiella </span>species, <span class="Italics">Proteus mirabilis</span>, <span class="Italics">Proteus vulgaris*</span>, <span class="Italics">Morganella morganii</span>, <span class="Italics">Providencia rettgeri*</span>, <span class="Italics">Pseudomonas </span>species, <span class="Italics">Serratia marcescens</span>, <span class="Italics">Bacteroides </span>species, and anaerobic cocci (including <span class="Italics">Peptostreptococcus* </span>species and <span class="Italics">Peptococcus </span>species).</p>
<p><span class="Bold">(6) Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> </span>including <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> caused by <span class="Italics">Streptococcus </span>species*, <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella </span>species, <span class="Italics">Bacteroides </span>species, and anaerobic cocci (including <span class="Italics">Peptostreptococcus* </span>species and <span class="Italics">Peptococcus* </span>species) <span class="Italics">Proteus mirabilis*</span>, and <span class="Italics">Clostridium </span>species*.</p>
<p><span class="Bold">(7) Bone and/or <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">joint infections</span> </span>caused by <span class="Italics">Staphylococcus aureus </span>(penicillinase and nonâ€‘penicillinase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Streptococcus </span>species (including <span class="Italics">S. pyogenes*</span>), <span class="Italics">Pseudomonas </span>species (including <span class="Italics">P. aeruginosa*</span>), and <span class="Italics">Proteus mirabilis*</span>.</p>
<p><span class="Bold">(8) Central nervous system <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, </span>e.g., <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> and ventriculitis, caused by <span class="Italics">Neisseria meningitidis</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Klebsiella pneumoniae* </span>and <span class="Italics">Escherichia coli*</span>.</p>
<p>(*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>Although many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterococci (e.g., <span class="Italics">S. faecalis</span>) and <span class="Italics">Pseudomonas </span>species are resistant to cefotaxime sodium <span class="Italics">in vitro</span>, Cefotaxime for Injection, USP has been used successfully in treating patients with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible organisms. </p>
<p>Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.</p>
<p>In certain cases of confirmed or suspected gram-positive or gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> or in patients with other serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in which the causative organism has not been identified, Cefotaxime for Injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the patientâ€™s condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> and <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> of aminoglycoside antibiotics. It is possible that <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> may be potentiated if Cefotaxime for Injection, USP is used concomitantly with an aminoglycoside.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_55caf552-2148-4c82-bf1d-4648251e3da1"></a><a name="section-4.2"></a><p></p>
<h2><span class="Bold">Prevention</span></h2>
<p class="First">The administration of Cefotaxime for Injection, USP preoperatively reduces the incidence of certain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in patients undergoing surgical procedures (e.g., abdominal or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or potentially contaminated.</p>
<p>In patients undergoing cesarean section, intraoperative (after clamping the umbilical cord) and postoperative use of Cefotaxime for Injection, USP may also reduce the incidence of certain <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infections</span>. SeeÂ <span class="Bold"><span class="Bold"><a href="#LINK_d73f4210-34b9-40b5-8670-470fd844c25a">DOSAGE AND ADMINISTRATION</a></span>Â </span>section. </p>
<p>Effective use for elective surgery depends on the time of administration. To achieve effective tissue levels, Cefotaxime for Injection, USP should be given 1/2 or 1 1/2 hours before surgery. SeeÂ <span class="Bold"><span class="Bold"><a href="#LINK_d73f4210-34b9-40b5-8670-470fd844c25a">DOSAGE AND ADMINISTRATION</a></span>Â </span>section.</p>
<p>For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as with a non- absorbable antibiotic (e.g., neomycin) is recommended.</p>
<p>If there are signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, specimens for culture should be obtained for identification of the causative organism so that appropriate therapy may be instituted.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefotaxime for Injection, USP and other antibacterial drugs, Cefotaxime for Injection, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_b147b930-814d-4d59-88c5-396d4a1cf269"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Cefotaxime is contraindicated in patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to cefotaxime sodium, or the cephalosporin group of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_8c33080a-b623-4f93-9bd1-82a99d7de97c"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">BEFORE THERAPY WITH CEFOTAXIME IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFOTAXIME SODIUM, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN WITH CAUTION TO PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">TYPE I HYPERSENSITIVITY</span> REACTIONS TO PENICILLIN. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGY</span>, PARTICULARLY TO DRUGS. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFOTAXIME OCCURS, DISCONTINUE TREATMENT WITH THE DRUG. SERIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE EPINEPHRINE AND OTHER EMERGENCY MEASURES.</p>
<p>During post-marketing surveillance, a potentially life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> was reported in each of six patients who received a rapid (less than 60 seconds) bolus injection of cefotaxime through a central venous catheter. Therefore, cefotaxime should only be administered as instructed in theÂ <span class="Bold"><span class="Bold"><a href="#LINK_d73f4210-34b9-40b5-8670-470fd844c25a">DOSAGE AND ADMINISTRATION</a></span>Â </span>section.</p>
<p><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including cefotaxime, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_fea22e6a-5856-4fc4-a6b2-ee67d3991990"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_873bb238-afb3-414d-9567-30f71a971806"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First">Prescribing cefotaxime in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Cefotaxime should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. </p>
<p>Because high and prolonged serum antibiotic concentrations can occur from usual doses in patients with transient or persistent reduction of urinary output because of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, the total daily dosage should be reduced when cefotaxime is administered to such patients. Continued dosage should be determined by degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and susceptibility of the causative organism.</p>
<p>Although there is no clinical evidence supporting the necessity of changing the dosage of cefotaxime sodium in patients with even profound renal dysfunction, it is suggested that, until further data are obtained, the dose of cefotaxime sodium be halved in patients with estimated creatinine clearances of less than 20 mL/min/1.73 m<span class="Sup">2</span>.</p>
<p>When only serum creatinine is available, the following formula<span class="Sup">5</span> (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function.</p>
<p><span class="Underline">Weight (kg) x (140 - age)</span></p>
<p>Males:Â Â  72 Ã— serum creatinine</p>
<p>Females: 0.85 Ã— above value</p>
<p>As with other antibiotics, prolonged use of cefotaxime may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patientâ€™s condition is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.</p>
<p>As with other beta-lactam antibiotics, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> and, more rarely, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> may develop during treatment with cefotaxime, particularly if given over long periods. For courses of treatment lasting longer than 10 days, blood counts should therefore be monitored.</p>
<p>Cefotaxime, like other parenteral anti-infective drugs, may be locally irritating to tissues. In most cases, perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of cefotaxime responds to changing of the infusion site. In rare instances, extensive perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of cefotaxime may result in tissue damage and require surgical treatment. To minimize the potential for tissue <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, infusion sites should be monitored regularly and changed when appropriate.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_834e3811-18aa-443c-90d7-3390592b00f9"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">Information for patients</span></h2>
<p class="First">Patients should be counseled that antibacterial drugs including cefotaxime should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When cefotaxime is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefotaxime or other antibacterial drugs in the future. </p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_daf184d8-f800-49d7-88d4-643247f15d88"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First">Increased <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics. </p>
<p>Probenecid interferes with the renal tubular transfer of cefotaxime, decreasing the total clearance of cefotaxime by approximately 50% and increasing the plasma concentrations of cefotaxime. Administration of cefotaxime in excess of 6 grams/day should be avoided in patients receiving probenecid (see <span class="Bold"><a href="#LINK_5383a41b-4191-4879-8ab4-6ba01f146d7a">CLINICAL PHARMACOLOGY, Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_4997d240-1084-4bb9-ad55-730caa6a9521"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">Drug/Laboratory Test Interactions</span></h2>
<p class="First">Cephalosporins, including cefotaxime sodium, are known to occasionally induce a positive direct Coombsâ€™ test.</p>
<p>A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedictâ€™s or Fehlingâ€™s solution or with CLINITEST<span class="Sup">Â®</span> tablets), but not with enzyme-based tests for <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> (e.g., CLINISTIX<span class="Sup">Â®</span> or TesTape<span class="Sup">Â®</span>). There are no reports in published literature that link elevations of plasma glucose levels to the use of cefotaxime.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_fbc75a0e-a38b-4ddf-b918-f2f2618e620b"></a><a name="section-7.5"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis</span></h2>
<p class="First">Lifetime studies in animals to evaluate carcinogenic potential have not been conducted. Cefotaxime was not mutagenic in the mouse micronucleus test or in the Ames test. Cefotaxime did not impair fertility to rats when administered subcutaneously at doses up to 250 mg/kg/dayÂ (0.2 times the maximum recommended human dose based on mg/m<span class="Sup">2</span>) or in mice when administered intravenously at doses up to 2000 mg/kg/day (0.7 times the recommended human dose based on mg/m<span class="Sup">2</span>).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_b859aa5b-680a-4a73-9408-0f1ff91380d1"></a><a name="section-7.6"></a><p></p>
<h2><span class="Bold">Pregnancy: Teratogenic Effects: Pregnancy Category B:</span></h2>
<p class="First">Reproduction studies have been performed in pregnant mice given cefotaxime intravenously at doses up to 1200 mg/kg/day (0.4 times the recommended human dose based on mg/m<span class="Sup">2</span>) or in pregnant rats when administered intravenously at doses up to 1200 mg/kg/day (0.8 times the recommended human dose based on mg/m<span class="Sup">2</span>). No evidence of embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was seen in these studies. Although cefotaxime has been reported to cross the placental barrier and appear in cord blood, the effect on the human fetus is not known. There are no well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_50e5f0dc-c912-49fb-a047-5ac83be8302a"></a><a name="section-7.6.1"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Use of the drug in women of child-bearing potential requires that the anticipated benefit be weighed against the possible risks.</p>
<p>Â </p>
<p>In perinatal and postnatal studies with rats, the pups in the group given 1200 mg/kg/day of cefotaxime were significantly lighter in weight at birth and remained smaller than pups in the control group during the 21 days of nursing.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_a366f5cd-4e02-4740-bd6b-fb528ad729d4"></a><a name="section-7.7"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when cefotaxime is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_cea8b85c-b1ee-4853-b004-e8be2fa3ab26"></a><a name="section-7.8"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">See<span class="Bold">Â <a href="#LINK_fea22e6a-5856-4fc4-a6b2-ee67d3991990">PRECAUTIONS</a></span> above regarding perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_be3b0024-67da-4a94-95e2-a0c8da54384d"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the 1409 subjects in clinical studies of cefotaxime, 632 (45%) were 65 and over, while 258 (18%) were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Â </p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <span class="Bold"><a href="#LINK_873bb238-afb3-414d-9567-30f71a971806">PRECAUTIONS, General</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_0a39c381-9d3c-4af9-ae4d-6c621867716c"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_56c7320d-8976-411f-90b7-a8888738e190"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold">Clinical Trials Experience</span></h2>
<p class="First">Cefotaxime is generally well tolerated. The most common adverse reactions have been local reactions following IM or IV injection.</p>
<p>Other adverse reactions have been encountered infrequently.</p>
<p><span class="Bold">The most frequent adverse reactions (greater than 1%) are:</span></p>
<p>Local (4.3%) - <span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">Injection site inflammation</span> with IV administration. <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> after IM injection. </p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (2.4%) - <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
<p>Gastrointestinal (1.4%) - <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Symptoms of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> can appear during or after antibiotic treatment. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> have been reported rarely.</p>
<p><span class="Bold">Less frequent adverse reactions (less than 1%) are:</span></p>
<p>Hematologic System - <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, transient <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, have been reported. Some individuals have developed positive direct Coombs Tests during treatment with cefotaxime and other cephalosporin antibiotics. </p>
<p>Genitourinary System - <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>.</p>
<p>Central Nervous System - <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>.</p>
<p>Liver - Transient elevations in AST, ALT, serum LDH, and serum alkaline phosphatase levels have been reported.</p>
<p>Kidney - As with some other cephalosporins, transient elevations of BUN have been occasionally observed with cefotaxime.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8ee8fbc6-e230-462d-bad9-a72341e244df"></a><a name="section-8.2"></a><p></p>
<h2><span class="Bold">Post-Marketing Experience</span></h2>
<p class="First">The following adverse reactions have been identified during post-approval use of cefotaxime. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Cardiovascular System - Potentially life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> following rapid (less than 60Â seconds) bolus administration via central venous catheter have been observed.</p>
<p>Central Nervous System - Administration of high doses of beta-lactam antibiotics, including cefotaxime, particularly in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> may result in <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> (e.g. impairment of consciousness, abnormal movements and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>). </p>
<p>Cutaneous - As with other cephalosporins, isolated cases of <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, </p>
<p>Stevensâ€‘Johnson syndrome, and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> have been reported.</p>
<p>Hematologic System - <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> - <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> (e.g., <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> possibly culminating in <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. </p>
<p>Kidney - Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, transient elevations of creatinine.</p>
<p>Liver - <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, elevations of gamma GT and bilirubin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e1b6477c-816d-4f84-92c8-34d1db397d47"></a><a name="section-8.3"></a><p></p>
<h2>Cephalosporin Class Labeling</h2>
<p class="First">In addition to the adverse reactions listed above which have been observed in patients treated with cefotaxime sodium, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and false-positive test for urinary glucose.</p>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the dosage was not reduced. SeeÂ <span class="Bold"><span class="Bold"><a href="#LINK_d73f4210-34b9-40b5-8670-470fd844c25a">DOSAGE AND ADMINISTRATION</a>Â </span></span>and <span class="Bold"><a href="#LINK_c68ba391-4241-460f-889f-425f4fc268fb">OVERDOSAGE</a></span>. If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceutical Corp. at 1-877â€‘233-2001 orÂ FDA at 1-800-FDA-1088 or <a href="#medwatch">www.fda.gov/medwatch</a>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_c68ba391-4241-460f-889f-425f4fc268fb"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The acute toxicity of cefotaxime was evaluated in neonatal and adult mice and rats. Significant mortality was seen at parenteral doses in excess of 6000 mg/kg/day in all groups. Common toxic signs in animals that died were a decrease in spontaneous activity, tonic and <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic convulsions</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>. Cefotaxime sodium overdosage has occurred in patients. Most cases have shown no overt toxicity. The most frequent reactions were elevations of BUN and creatinine. There is a risk of reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> in cases of administration of high doses of beta-lactam antibiotics including cefotaxime.Â  No specific antidote exists. Patients who receive an acute overdosage should be carefully observed and given supportive treatment.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_d73f4210-34b9-40b5-8670-470fd844c25a"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The intent of this Pharmacy Bulk Package is for the preparation of solutions for intravenous infusion only. Dosing references to the intramuscular route of administration are for informational purposes only.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0e056d63-ba75-47cd-b4fb-a99c9d80e7ed"></a><a name="section-10.1"></a><p></p>
<h2><span class="Bold">Adults</span></h2>
<p class="First">Dosage and route of administration should be determined by susceptibility of the causative organisms, severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and the condition of the patient (see table for dosage guideline). Cefotaxime may be administered IM or IV after reconstitution. The maximum daily dosage should not exceed 12 grams.</p>
<table>
<caption><span>GUIDELINES FOR DOSAGE OF CEFOTAXIME FOR INJECTION</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">
<span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span>Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">Daily Dose<br>(grams)</span>Â </td>
<td class="Botrule Lrule Rrule Toprule">
<span class="Bold">Â Frequency and Route</span>Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Gonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span>/<span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span> in males and females</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0.5</td>
<td class="Botrule Lrule Rrule Toprule">Â 0.5 gram IM (single dose)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Rectal <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> in females</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0.5</td>
<td class="Botrule Lrule Rrule Toprule">Â 0.5 gram IM (single dose)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Rectal <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> in males</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1</td>
<td class="Botrule Lrule Rrule Toprule">Â 1 gram IM (single dose)Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Uncomplicated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 2</td>
<td class="Botrule Lrule Rrule Toprule">Â 1 gram every 12 hours IM or IV</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Moderate to severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 3-6</td>
<td class="Botrule Lrule Rrule Toprule">Â 1-2 grams every 8 hours IM or IV</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> commonly needing antibiotics in higher dosage (e.g., <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6-8</td>
<td class="Botrule Lrule Rrule Toprule">Â 2 grams every 6-8 hours IV</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Â Life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â up to 12</td>
<td class="Botrule Lrule Rrule Toprule">Â 2 grams every 4 hours IV</td>
</tr>
</tbody>
</table>
<br><p>If <span class="Italics">C. trachomatis </span>is a suspected pathogen, appropriate anti-chlamydial coverage should be added, because cefotaxime sodium has no activity against this organism.</p>
<p>To prevent <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infection</span> in contaminated or potentially contaminated surgery, the recommended dose is a single 1 gram IM or IV administered 30 to 90 minutes prior to start of surgery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b2857e04-62c1-4284-a0e2-82d9a74cc9fe"></a><a name="section-10.2"></a><p></p>
<h2><span class="Bold">Cesarean Section Patients</span></h2>
<p class="First">The first dose of 1 gram is administered intravenously as soon as the umbilical cord is clamped. The second and third doses should be given as 1 gram intravenously or intramuscularly at 6 and 12Â hours after the first dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9dde19ed-d511-43a6-a0b2-09b038861209"></a><a name="section-10.3"></a><p></p>
<h2><span class="Bold">Neonates, Infants, and Children</span></h2>
<p class="First">The following dosage schedule is recommended: </p>
<p><span class="Underline">Neonates (birth to 1 month):</span></p>
<p>0-1 week of age 50 mg/kg per dose every 12 hours IV</p>
<p>1-4 weeks of age 50 mg/kg per dose every 8 hours IV</p>
<p>It is not necessary to differentiate between premature and normal-gestational age infants. </p>
<p><span class="Underline">Infants and Children (1 month to 12 years):</span></p>
<p>For body weights less than 50 kg, the recommended daily dose is 50 to 180 mg/kg IM or IV body weight divided into four to six equal doses. The higher dosages should be used for more severe or serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. For body weights 50 kg or more, the usual adult dosage should be used; the maximum daily dosage should not exceed 12 grams.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_5f54ac56-eae0-4d8b-938d-18c4b3c84d6f"></a><a name="section-10.4"></a><p></p>
<h2><span class="Bold">Geriatric Use</span></h2>
<p class="First">This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (SeeÂ <span class="Bold"><span class="Bold"><a href="#LINK_873bb238-afb3-414d-9567-30f71a971806">PRECAUTIONS, General</a></span>Â </span>and <span class="Bold"><a href="#LINK_be3b0024-67da-4a94-95e2-a0c8da54384d">PRECAUTIONS, Geriatric Use</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5bc5367f-e0e0-43c4-8580-fe9460b6e243"></a><a name="section-10.5"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></h2>
<p class="First">See <span class="Bold"><a href="#LINK_873bb238-afb3-414d-9567-30f71a971806">PRECAUTIONS, General</a></span>.</p>
<p><span class="Bold">NOTE: </span>As with antibiotic therapy in general, administration of cefotaxime should be continued for a minimum of 48 to 72 hours after the patient defervesces or after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by Group A beta-hemolytic streptococci in order to guard against the risk of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> or <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> and may be required for several months after therapy has been completed; persistent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may require treatment of several weeks and doses smaller than those indicated above should not be used.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_508fd51b-2913-4bf4-9e39-b14c4c371098"></a><a name="section-10.6"></a><p></p>
<h2><span class="Italics">DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE:</span></h2>
<p class="First">The 10 gram Pharmacy Bulk Package should be penetrated ONLY ONE TIME utilizing a suitable sterile transfer device or dispensing set and should be reconstituted with 47 mL of diluent for an approximate concentration of 200Â mg/mL (withdrawable volume 52 mL) or 97 mL of diluent for an approximate concentration of 100 mg/mL withdrawable volume 102 mL), in a suitable work area such as a laminar flow hood, using aseptic technique. Shake to dissolve; inspect for particulate matter and discoloration prior to use. Stock solutions may be further diluted for IV infusion with diluents as listed inÂ <span class="Bold"><span class="Bold"><a href="#LINK_b96a50c5-7646-4089-b1be-8b0e6b289b0c">COMPATIBILITY AND STABILITY</a></span>Â </span>section. The reconstituted content of the 10 g Pharmacy Bulk Package should be withdrawn immediately, using a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents. However, if it is not possible, aliquoting operations must be completed within four hours of reconstitution. Discard the reconstituted stock solution 4 hours after initial entry. Solutions of cefotaxime range from very <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow to light amber, depending on concentration, diluent used, and length and condition of storage.</p>
<table border="0" cellpadding="0" cellspacing="0">
<col>
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Reconstituted Bulk Solutions Should Not Be Used For Direct Infusion</span></p></td></tr></tbody>
</table>
<p><span class="Bold">NOTE: </span>Solutions of cefotaxime must not be admixed with aminoglycoside solutions. If cefotaxime and aminoglycosides are to be administered to the same patient, they must be administered separately and not as mixed injection.</p>
<p>A SOLUTION OF 1 G CEFOTAXIME IN 14 ML OF STERILE WATER FOR INJECTION IS ISOTONIC.</p>
<p><span class="Bold">IM Administration: </span>As with all IM preparations, cefotaxime should be injected well within the body of a relatively large muscle such as the upper outer quadrant of the buttock (i.e., gluteus maximus); <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> is necessary to avoid inadvertent injection into a blood vessel. Individual IM doses of 2 grams may be given if the dose is divided and is administered in different intramuscular sites.</p>
<p><span class="Bold">IV Administration: </span>The IV route is preferable for patients with <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, or other severe or life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as <span class="product-label-link" type="condition" conceptid="4090739" conceptname="Nutritional disorder">malnutrition</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or malignancy, particularly if <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> is present or impending.</p>
<p>For intermittent IV administration, a solution containing 1 gram or 2 grams in 10 mL of Sterile Water for Injection can be injected over a period of three to five minutes. Cefotaxime should not be administered over a period of less than three minutes. (See <span class="Bold"><a href="#LINK_8c33080a-b623-4f93-9bd1-82a99d7de97c">WARNINGS</a></span>). With an infusion system, it may also be given over a longer period of time through the tubing system by which the patient may be receiving other IV solutions. However, during infusion of the solution containing cefotaxime, it is advisable to discontinue temporarily the administration of other solutions at the same site.</p>
<p>For the administration of higher doses by continuous IV infusion, a solution of cefotaxime may be added to IV bottles containing the solutions discussed below.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b96a50c5-7646-4089-b1be-8b0e6b289b0c"></a><a name="section-10.7"></a><p></p>
<h2>COMPATIBILITY AND STABILITY</h2>
<p class="First">Solutions of cefotaxime reconstituted as described above (<span class="Italics"><a href="#LINK_508fd51b-2913-4bf4-9e39-b14c4c371098">DIRECTIONS FOR PROPER USE OF PHARMACY BULK PACKAGE</a></span>) should be discarded 4 hours after initial entry.</p>
<p>Reconstituted solutions may be further diluted up to 1000 mL with the following solutions and maintain satisfactory potency for 24 hours at or below 22Â°C, and at least 5 days under refrigeration (at or below 5Â°C): 0.9% Sodium Chloride Injection; 5 or 10% Dextrose Injection; 5% Dextrose and 0.9% Sodium Chloride Injection, 5% Dextrose and 0.45% Sodium Chloride Injection; 5% Dextrose and 0.2% Sodium Chloride Injection; Lactated Ringerâ€™s Solution; Sodium Lactate Injection (M/6); 10% Invert Sugar Injection, 8.5% TRAVASOL<span class="Sup">Â®</span> (Amino Acid) Injection without Electrolytes.</p>
<p><span class="Bold">NOTE: </span>Cefotaxime solutions exhibit maximum stability in the pH 5-7 range. Solutions of cefotaxime should not be prepared with diluents having a pH above 7.5, such as Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Injection.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_f5735090-14ca-4123-868a-040434c7b601"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Sterile Cefotaxime for Injection, USP, in Pharmacy Bulk Packages, is a dry off-white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline powder containing cefotaxime sodium as follows:</p>
<p>10 g cefotaxime (free acid equivalent) in bottles, packages of 1 (NDC 0143-9935-01); <span class="Bold">NOT FOR DIRECT ADMINISTRATION.</span></p>
<p><span class="Bold">Also available:</span></p>
<p>500 mg cefotaxime (free acid equivalent) vials in packages of 10 (NDC 0143-9930-10)</p>
<p>1 g cefotaxime (free acid equivalent) vials in packages of 25 (NDC 0143-9931-25)</p>
<p>2 g cefotaxime (free acid equivalent) vials in packages of 25 (NDC 0143-9933-25) </p>
<p><span class="Bold">NOTE: </span>Cefotaxime for Injection, USP in the dry state should be stored at 20Âº to 25Â°C (68Âº to 77Â°F) [See USP Controlled Room Temperature].</p>
<p>The dry material as well as solutions tend to darken depending on storage conditions and should be protected from elevated temperatures and excessive light.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_c648ca21-6336-47e6-aab8-5128ca9e89fb"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution AntimicrobialÂ  Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition. CLSI document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobials Susceptibility Tests; Twenty-Third Informational Supplement. CLSI document M100-S23, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2013.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - Eleventh Edition. CLSI document M02-A11, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - Eighth Edition. CLSI document M11-A8,Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</li>
<li>Cockcroft, D.W. and Gault, M.H.: Prediction of Creatinine Clearance from Serum Creatinine, Nephron 16:31â€“41, 1976. </li>
</ol>
<p class="First">Travasol<span class="Sup">Â®</span> is manufactured by Clintec.Â </p>
<p>Â </p>
<p>Â </p>
<p>Â </p>
<p><span class="Bold">Manufactured by:</span></p>
<p>HIKMA FARMACÃŠUTICA (PORTUGAL), S.A.</p>
<p>Estrada do Rio da MÃ³, 8, 8A e 8B - FervenÃ§a - 2705 â€“ 906 Terrugem SNT, PORTUGAL</p>
<p>Â </p>
<p><span class="Bold">Distributed by:</span></p>
<p>WEST-WARD PHARMACEUTICAL CORP. </p>
<p>Eatontown, NJ 07724 USA</p>
<p>Â </p>
<p>Â </p>
<p>Revised:Â June 2014 </p>
<p>PIN106-WES/4</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_fe80e6f3-82e2-4945-8b96-28c3c2e9c7c3"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0143-9935-01<br><span class="Bold">CEFOTAXIME</span><br>FOR INJECTION, USP</p>
<table>
<col>
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">PHARMACY BULK PACKAGE<br>NOT FOR DIRECT INFUSION</span>Â </td></tr></tbody>
</table>
<p>10 grams* per Pharmacy Bulk Package<br>NOT TO BE DISPENSED AS A UNIT<br>FOR IV USE ONLY<br>Rx ONLY</p>
<p><span class="Bold">This Pharmacy Bulk Package is intended for preparing IV admixtures only. See<br>insert for complete dosage information and proper use of the container. </span></p>
<p>*Each vial contains sterile cefotaxime sodium equivalent to 10 g of cefotaxime. The<br>sodium content is approximately 50.5 mg (2.2 mEq) of sodium per gram of cefotaxime.</p>
<p><span class="Bold">USUAL DOSAGE: </span>See package insert. Reconstitute with suitable diluents as listed<br>in the package insert. <span class="Bold">Shake to dissolve.</span></p>
<p><span class="Bold">Storage: </span>Cefotaxime for Injection, USP in the dry state should be stored at 20Âº to<br>25ÂºC (68Âº to 77ÂºF) [See USP Controlled Room Temperature]. <span class="Bold">PROTECT FROM LIGHT.</span></p>
<p><span class="Bold">RETAIN IN CARTON UNTIL TIME OF USE</span>.</p>
<p>Withdraw reconstituted contents immediately. However, if it is not possible,<br>aliquoting operations must be completed within 4 hours of reconstitution.<br>Discard reconstituted stock solution 4 hours after initial entry.</p>
<table>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Concentration of the SolutionÂ </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">Amount of Diluent</span>Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1 g/5 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center">47 mLÂ </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1 g/10 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center">97 mLÂ </td>
</tr>
</tbody>
</table>
<table>
<col>
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">Â Date Prepared: _________________ Do Not Use After: _____________________________</td></tr></tbody>
</table>
<div class="Figure"><img alt="NDC 0143-9935-01 CEFOTAXIME FOR INJECTION, USP PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION 10 grams* per Pharmacy Bulk Package NOT TO BE DISPENSED AS A UNIT FOR IV USE ONLY Rx ONLY This Pharmacy Bulk Package is intended for preparing IV admixtures only. See insert for complete dosage information and proper use of the container." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ef1a6dc6-bc3d-4f09-8f92-7ff328f56561&amp;name=cefotaxime-for-injection-pbp-2.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFOTAXIMEÂ 		
					</strong><br><span class="contentTableReg">cefotaxime injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0143-9935</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFOTAXIME SODIUM</strong> (CEFOTAXIME) </td>
<td class="formItem">CEFOTAXIME</td>
<td class="formItem">10Â g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0143-9935-01</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065071</td>
<td class="formItem">11/20/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>West-Ward Pharmaceutical Corp
							(001230762)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">HIKMA FARMACEUTICA (PORTUGAL), S.A</td>
<td class="formItem"></td>
<td class="formItem">452742943</td>
<td class="formItem">ANALYSIS(0143-9935), LABEL(0143-9935), MANUFACTURE(0143-9935), PACK(0143-9935)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6ce0c3b7-f66f-4615-885b-781776832394</div>
<div>Set id: ef1a6dc6-bc3d-4f09-8f92-7ff328f56561</div>
<div>Version: 7</div>
<div>Effective Time: 20140730</div>
</div>
</div>Â <div class="DistributorName">West-Ward Pharmaceutical Corp</div></p>
</body></html>
